Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: findings from a randomised trial.

Huang PY, Wang CT, Cao KJ, Guo X, Guo L, Mo HY, Wen BX, Wu YS, Mai HQ, Hong MH.

Eur J Cancer. 2013 May;49(8):1923-31. doi: 10.1016/j.ejca.2013.01.027.

PMID:
23434149
2.

Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.

Huang PY, Zeng Q, Cao KJ, Guo X, Guo L, Mo HY, Wu PH, Qian CN, Mai HQ, Hong MH.

Eur J Cancer. 2015 Sep;51(13):1760-70. doi: 10.1016/j.ejca.2015.05.025.

PMID:
26093812
3.

High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma.

Wan XB, Wei L, Li H, Dong M, Lin Q, Ma XK, Huang PY, Wen JY, Li X, Chen J, Ruan DY, Lin ZX, Chen ZH, Liu Q, Wu XY, Hong MH.

Eur J Cancer. 2013 Jul;49(10):2356-64. doi: 10.1016/j.ejca.2013.03.008.

PMID:
23541571
4.

[Concurrent chemoradiotherapy followed by adjuvant chemotherapy for stage III-IVa nasopharyngeal carcinoma].

Hu QY, Liu P, Wang L, Fu ZF.

Ai Zheng. 2007 Apr;26(4):394-7. Chinese.

PMID:
17430659
5.
6.
7.

[Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].

Zou GR, Zhang YJ, Xie FY, Zheng W, Li HX, Xia YF, Lin TY, Lu TX.

Ai Zheng. 2006 Dec;25(12):1543-9. Chinese.

PMID:
17166383
8.

A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma.

Huang PY, Cao KJ, Guo X, Mo HY, Guo L, Xiang YQ, Deng MQ, Qiu F, Cao SM, Guo Y, Zhang L, Li NW, Sun R, Chen QY, Luo DH, Hua YJ, Mai HQ, Hong MH.

Oral Oncol. 2012 Oct;48(10):1038-44. doi: 10.1016/j.oraloncology.2012.04.006.

PMID:
22591726
9.

Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.

Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, Li NW, Xiang YQ, Luo DH, Qiu F, Sun R, Deng MQ, Chen MY, Hua YJ, Guo X, Cao KJ, Hong MH, Qian CN, Mai HQ.

J Natl Cancer Inst. 2011 Dec 7;103(23):1761-70. doi: 10.1093/jnci/djr432.

PMID:
22056739
11.

Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.

Loong HH, Ma BB, Leung SF, Mo F, Hui EP, Kam MK, Chan SL, Yu BK, Chan AT.

Radiother Oncol. 2012 Sep;104(3):300-4. doi: 10.1016/j.radonc.2011.12.022.

PMID:
22300609
12.

Prognostic features and treatment outcome in locoregionally advanced nasopharyngeal carcinoma following concurrent chemotherapy and radiotherapy.

Cheng SH, Jian JJ, Tsai SY, Chan KY, Yen LK, Chu NM, Tan TD, Tsou MH, Huang AT.

Int J Radiat Oncol Biol Phys. 1998 Jul 1;41(4):755-62.

PMID:
9652835
13.

Overweight/obese status associates with favorable outcome in patients with metastatic nasopharyngeal carcinoma: a 10-year retrospective study.

Li W, Shen LJ, Chen T, Sun XQ, Zhang Y, Wu M, Shu WH, Chen C, Pan CC, Xia YF, Wu PH.

Chin J Cancer. 2016 Aug 9;35(1):75. doi: 10.1186/s40880-016-0139-6.

14.

Body mass index as a prognostic factor in epithelial ovarian cancer and correlation with clinico-pathological factors.

Skírnisdóttir I, Sorbe B.

Acta Obstet Gynecol Scand. 2010;89(1):101-7. doi: 10.3109/00016340903322735.

PMID:
19878086
15.

Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy.

Hua YJ, Han F, Lu LX, Mai HQ, Guo X, Hong MH, Lu TX, Zhao C.

Eur J Cancer. 2012 Dec;48(18):3422-8. doi: 10.1016/j.ejca.2012.06.016.

PMID:
22835782
16.

Another way to estimate outcome of advanced nasopharyngeal carcinoma--is concurrent chemoradiotherapy adequate?

Lin JC, Liang WM, Jan JS, Jiang RS, Lin AC.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):156-64.

PMID:
15337551
17.

[Long-term efficacy of induction chemotherapy plus concurrent radiochemotherapy on advanced nasopharyngeal carcinoma].

Liang Y, Gao JM, Hu WH, Gao YH, Xie FY.

Ai Zheng. 2007 Aug;26(8):885-9. Chinese.

PMID:
17697553
18.

Polymorphisms in the endothelin-1 and endothelin a receptor genes and survival in patients with locoregionally advanced nasopharyngeal carcinoma.

Wen YF, Qi B, Liu H, Mo HY, Chen QY, Li J, Huang PY, Ye YF, Zhang Y, Deng MQ, Guo X, Hong MH, Cao KJ, Mai HQ.

Clin Cancer Res. 2011 Apr 15;17(8):2451-8. doi: 10.1158/1078-0432.CCR-10-2264.

19.
20.

[Effect of hypoxic radiosensitizer sodium glycididazole on long-term result of radiotherapy for nasopharyngeal carcinoma].

Liu MZ, He LR, Lu TX, Chen YY, Hu YH, Cui NJ, Xu GZ, Gao L, Xiao GL, Zhang SW, Cai Y, Li DM, Chen LH, Wang FY, Sun Q, Zhu L, Sheng G, Gao HJ, Bao YH.

Zhonghua Zhong Liu Za Zhi. 2006 Dec;28(12):932-7. Chinese.

PMID:
17533747

Supplemental Content

Support Center